Янв
15,
2025
Янв 15, 2025
Massagno, Switzerland
Lallemand Pharma and GM PHARMA (GM Pharmaceuticals LTD) are thrilled to announce their partnership for the launch of Healsea®, a new nasal spray designed to advance respiratory treatment conditions in Georgia. This collaboration marks a significant milestone in the ongoing relationship between the two companies, with GM PHARMA already being a long-standing partner for PMBL.
Healsea® represents a new step forward in respiratory care, offering innovative solutions for patients suffering from various respiratory conditions. The nasal spray is expected to provide effective relief and improve the quality of life for many individuals.
«We are excited to bring Healsea® to the Georgian market through our partnership with GM PHARMA», said Frédéric Durmont, General Manager at Lallemand Pharma. «This collaboration underscores our commitment to delivering advanced healthcare solutions and enhancing patient outcomes.»
GM PHARMA has been a trusted partner in the region, and their expertise in licensing and distributing pharmaceutical products will be instrumental in the successful launch of Healsea®. The introduction of this nasal spray aligns with both companies’ dedication to improving respiratory health and providing accessible treatment options.
«We are proud to continue our partnership with Lallemand Pharma and to introduce Healsea® to our portfolio», said Levan Varduashvili, CEO at GM PHARMA. «This product launch is a testament to our shared vision of advancing healthcare and offering innovative treatments to our patients.»
Congratulations to the entire team involved in making this partnership and product launch a reality. Together, Lallemand Pharma and GM PHARMA are poised to make a significant impact on respiratory health in Georgia.